JP2009538276A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538276A5
JP2009538276A5 JP2009507606A JP2009507606A JP2009538276A5 JP 2009538276 A5 JP2009538276 A5 JP 2009538276A5 JP 2009507606 A JP2009507606 A JP 2009507606A JP 2009507606 A JP2009507606 A JP 2009507606A JP 2009538276 A5 JP2009538276 A5 JP 2009538276A5
Authority
JP
Japan
Prior art keywords
deoxynojirimycin
pentane
neopentyloxy
methoxy
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009507606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538276A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2007/050177 external-priority patent/WO2007123403A1/en
Publication of JP2009538276A publication Critical patent/JP2009538276A/ja
Publication of JP2009538276A5 publication Critical patent/JP2009538276A5/ja
Ceased legal-status Critical Current

Links

JP2009507606A 2006-04-24 2007-04-24 嚢胞性線維症の改良型治療 Ceased JP2009538276A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79408806P 2006-04-24 2006-04-24
PCT/NL2007/050177 WO2007123403A1 (en) 2006-04-24 2007-04-24 Improved treatment of cystic fibrosis

Publications (2)

Publication Number Publication Date
JP2009538276A JP2009538276A (ja) 2009-11-05
JP2009538276A5 true JP2009538276A5 (https=) 2010-04-08

Family

ID=38283020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507606A Ceased JP2009538276A (ja) 2006-04-24 2007-04-24 嚢胞性線維症の改良型治療

Country Status (10)

Country Link
US (1) US8410081B2 (https=)
EP (1) EP2010551B1 (https=)
JP (1) JP2009538276A (https=)
CN (1) CN101479288B (https=)
AT (1) ATE479696T1 (https=)
AU (1) AU2007241622A1 (https=)
BR (1) BRPI0710883A2 (https=)
CA (1) CA2650311A1 (https=)
DE (1) DE602007008870D1 (https=)
WO (1) WO2007123403A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0712494D0 (en) * 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
EP2398321B1 (en) 2009-02-23 2015-11-25 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
EP2400843B1 (en) * 2009-02-24 2015-11-11 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
ES2524361T3 (es) * 2009-06-12 2014-12-05 United Therapeutics Corporation Iminoazúcares para su uso en el tratamiento de enfermedades por bunyavirus y togavirus
CA2772813A1 (en) * 2009-09-04 2011-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Iminosugars and methods of treating filoviral diseases
JP5653438B2 (ja) * 2009-09-04 2015-01-14 ユナイテッド セラピューティクス コーポレイション オルトミクソウイルス感染の治療方法
CA2772807A1 (en) * 2009-09-04 2011-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Methods of treating poxviral infections
GB201000499D0 (en) 2010-01-13 2010-03-03 Fleet George W J Treatment of cystic fibrosis
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
GB201006434D0 (en) 2010-04-19 2010-06-02 Summit Corp Plc Novel iminosugar combinations
LT2753346T (lt) 2011-09-07 2020-08-10 Mount Sinai School Of Medicine Ceramidazė ir ląstelių diferenciacija
ES2897825T3 (es) * 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
EP2929346A1 (en) * 2012-12-05 2015-10-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Diagnosis of cystic fibrosis
PT2968479T (pt) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
EP3442514B1 (en) 2016-04-11 2021-06-16 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
PL3630725T3 (pl) 2017-06-01 2026-03-23 Idorsia Pharmaceuticals Ltd Postać krystaliczna n-butylodeoksygalaktonojirymycyny
KR20230169989A (ko) * 2021-03-12 2023-12-18 익셉젠 인크. 단백질 발현을 위한 시스템 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE322900T1 (de) 1996-07-15 2006-04-15 Macrozyme Dnm B V Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
AU5799500A (en) * 1999-06-29 2001-01-22 Mcgill University Human alpha 1,2-mannosidase
EP1528056A1 (en) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
US20100004156A1 (en) * 2005-07-27 2010-01-07 Shalesh Kaushal Small Compounds That Correct Protein Misfolding and Uses Thereof

Similar Documents

Publication Publication Date Title
JP2009538276A5 (https=)
JP2004519469A5 (https=)
JP2011513196A5 (https=)
JP2010504343A5 (https=)
HRP20150277T1 (hr) Modulatori atp-vezujuä†ih kasetnih transportera
JP2007016035A5 (https=)
JP2006526590A5 (https=)
JP2010502730A5 (https=)
JP2010528011A5 (https=)
JP2007514005A5 (https=)
JP2009535307A5 (https=)
JP2007501251A5 (https=)
JP2012502885A5 (https=)
JP2008539268A5 (https=)
JP2014508804A5 (https=)
JP2009500423A5 (https=)
JP2010511631A5 (https=)
ES2489265T3 (es) Asociación de inhibidores de la HMG-CoA reductasa atorvastatina o simvastatina con un inhibidor de la fosfodiesterasa 4, tal como roflumilast para el tratamiento de enfermedades pulmonares inflamatorias
JP2008546770A5 (https=)
WO2009064374A3 (en) Oral formulations of bis(thiohydrazide amides)
JP2000159790A5 (https=)
JP2008515980A5 (https=)
SE0401655D0 (sv) New compounds
JP2011068692A5 (https=)
EA200500240A1 (ru) Новый способ синтеза соединений 1,3,4,5-тетрагидро-2h-3-бензазепин-2-она и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой